Fecal calprotectin in differential diagnosis of irritable bowel syndrome

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third Hospital, Beijing 100083, China, reported in Beijing Da Xue Xue Bao. 2006 Jun 18;38(3):310-3, that fecal calprotectin as a non-invasive screening biomarker in the differential diagnosis of IBS and symptomatic chronic large intestinal organic disease was better than FOBT, ESR and CRP. It was simple, inexpensive, repeatable and no-invasive. It can be used as a biomarker in exclusion from related organic diseases before the diagnosis of irritable bowel syndrome. PMID: 16778979

CALPRO TEAM

General Information

Fecal calprotectin in differential diagnosis of irritable bowel syndrome

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third May 9, 2015

PhiCal Test FDA approved

The PhiCal Test has now been approved by the FDA for clinical use in the USA October 1, 2014

Latest News

Meet us at ECCO!

January 5, 2018

Calpro press release regarding MSD agreement

Please see the Calpro press release regarding MDS agreement for delivery of e-health technology CalproSmart:

Norsk | English October 13, 2016

View all latest

Share This